MX2024002857A - Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos. - Google Patents

Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos.

Info

Publication number
MX2024002857A
MX2024002857A MX2024002857A MX2024002857A MX2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A MX 2024002857 A MX2024002857 A MX 2024002857A
Authority
MX
Mexico
Prior art keywords
milvexian
prevention
treatment
thromboembolic disorders
thromboembolic
Prior art date
Application number
MX2024002857A
Other languages
English (en)
Spanish (es)
Inventor
Dietmar Alfred Seiffert
Gary Peters
Joseph M Luettgen
John Strony
Madhu Chintala
Christopher Nessel
Liyanage Vidya Perera
Danshi Li
Charlotte Jones-Burton
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2024002857A publication Critical patent/MX2024002857A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002857A 2021-09-17 2022-09-16 Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos. MX2024002857A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US202163278582P 2021-11-12 2021-11-12
PCT/US2022/043797 WO2023043999A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Publications (1)

Publication Number Publication Date
MX2024002857A true MX2024002857A (es) 2024-03-21

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002857A MX2024002857A (es) 2021-09-17 2022-09-16 Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos.

Country Status (11)

Country Link
US (1) US20250099466A1 (https=)
EP (1) EP4401736A1 (https=)
JP (1) JP2024534427A (https=)
KR (1) KR20240060820A (https=)
AU (1) AU2022345862A1 (https=)
CA (1) CA3232633A1 (https=)
CL (1) CL2024000776A1 (https=)
IL (1) IL310894A (https=)
MX (1) MX2024002857A (https=)
TW (1) TW202327607A (https=)
WO (1) WO2023043999A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) * 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
TW202506125A (zh) * 2023-04-19 2025-02-16 美商必治妥美雅史谷比公司 米爾維仙(milvexian)於治療及預防患有心血管或腦血管疾病之患者之血栓病況的用途
WO2024220803A1 (en) * 2023-04-19 2024-10-24 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation
EP4698172A1 (en) * 2023-04-19 2026-02-25 Bristol-Myers Squibb Company Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112021020257A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico

Also Published As

Publication number Publication date
CL2024000776A1 (es) 2024-07-26
AU2022345862A1 (en) 2024-03-14
IL310894A (en) 2024-04-01
JP2024534427A (ja) 2024-09-20
KR20240060820A (ko) 2024-05-08
EP4401736A1 (en) 2024-07-24
CA3232633A1 (en) 2023-03-23
US20250099466A1 (en) 2025-03-27
WO2023043999A1 (en) 2023-03-23
TW202327607A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
MX2024002857A (es) Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos.
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
JOP20230190A1 (ar) مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس
CY1122867T1 (el) Συνθεσεις που περιλαμβανουν ενα βακτηριακο στελεχος του blautia hydrogenotrophica για χρηση στην θεραπεια ή προληψη διαρροιας ή δυσκοιλιοτητας
MX2022000711A (es) Inhibidores de parp1.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CL2019000060A1 (es) Sulfonilureas y compuestos relacionados y uso de estos. (divisional solicitud 201702097)
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MX2024000349A (es) Compuestos y usos de los mismos.
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
BR112024001180A2 (pt) Composições e métodos para tratamento do melanoma
CO2019014647A2 (es) Composiciones inmunogénicas
MX2024006769A (es) Compuestos y usos de los mismos.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2021012359A (es) Inhibidores de la vía de señalización de notch y su uso en el tratamiento de cánceres.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2018014938A (es) Combinaciones farmaceuticas para el tratamiento del cancer.
EA202192047A1 (ru) Соединения и их применение
MX2025012183A (es) Formas cristalinas de un inhibidor de ras